Effective August 15, Blueprint Genetics will transition laboratory services to our global headquarters and laboratory in Helsinki, Finland and discontinue providing lab services from the US. For more information, please visit https://blueprintgenetics.com/us-lab-operations/.
Our panels include over 3,900 genes selected based on curated gene reviews, variant databases (HGMD and ClinVar), most recent literature, and customer requests. We offer enhanced clinical utility, maximized diagnostic yield, empowered differential diagnosis as well as analytically validated up-to-date genes across all our panels. Difficult-to-sequence genes are covered with high quality enabling true diagnostic impact in challenging patient cases.
Genetic testing in the field of neurology is becoming increasingly beneficial. NGS panels can lead to a notable increase in the diagnostic success rate, as well as potentially more rapid diagnoses, which has implications for health service economics and improved patient satisfaction.
Genetic testing using targeted capture followed by NGS is an efficient and cost-effective method of molecular diagnosis in many refractory ataxia cases (PMID: 24030952). Furthermore, genetic diagnosis using well-designed NGS panels has expanded the phenotypic spectrum of many genes to cover a broader range of diseases than ever before. With the current technology and careful interpretation of the detected variants, mutations in the same genes can be associated with a broad range of clinical and neuroimaging phenotypes.
What genetic diagnostics can offer patients with neurological diseases
All of the main neurological disease categories have a large number of subtypes with extensive phenotypic overlap, which complicates traditional clinical diagnosis. For example, disorders that were thought to be separate entities may actually represent a phenotypic continuum of a single entity, as was shown with Bethlem myopathy and Ullrich congenital muscular dystrophy. Genetic diagnostics is the most efficient way to subtype neurological diseases, and provides the necessary information to make confident individualized treatment and management decisions.
Living with a set of symptoms and findings without a definitive diagnosis can be stressful for patients, so finding a genetic cause may end a long diagnostic odyssey, and in many cases, a definite name may be relieving. Genetic diagnosis in neurological diseases has significant prognostic value, as disease progression can often be evaluated based on the underlying genetic defect.
Note: due to a temporary technical limitation the newsletter subscription form below does not load in some browsers if cookies have not been allowed. If you do not see the form below, please allow cookies by clicking here to open the cookie preference centre, then allow cookies and reload this page. You can disallow cookies once you have signed up if you wish.
In this educational webinar, Professor Moosajee presents recent work in genetic eye disorders, including discoveries, which may provide patients with an answer for their diagnosis, better guide management strategies, and define risks for family members.
The European Human Genetics Conference 2024 View our recording of Blueprint Genetics at the European Human Genetics Conference June 1–4, 2024 in Berlin, Germany.
In this webinar, we explore the genetic underpinnings of mitochondrial diseases, spotlighting the mitochondrial genome and the intricacies of mtDNA testing via next-generation sequencing.
Note: due to a temporary technical limitation the newsletter subscription form below does not load in some browsers if cookies have not been allowed. If you do not see the form below, please allow cookies by clicking here to open the cookie preference centre, then allow cookies and reload this page. You can disallow cookies once you have signed up if you wish.
Order a specimen kit
Please be advised that a specimen collection kit must be requested by a medical professional.
If you are a patient or family member of a patient, please contact your provider to place a kit order on your behalf.